Objective: Short-term weight loss is accompanied by bone loss in postmenopausal women. The longer-term impact of weight loss on bone in reduced overweight/obese women compared with women who regained their weight was examined in this study using a case-control design.
O bese and overweight people are strongly encouraged to lose 5% to 15% of their weight to reduce the risk of comorbid conditions. During the menopausal transition, women tend to gain weight and visceral adiposity; therefore, many of these women who were never overweight previously are now encouraged to reduce weight to improve health. However, studies show that weight loss in even obese and overweight women results in bone mineral density (BMD) loss of approximately 1% to 2% with 10% weight reduction and can partially be attenuated with certain interventions.
1<4 Loss of bone due to weight reduction is more consistently shown in older individuals compared with younger individuals. 4<7 In large retrospective studies, weight reduction whether weight loss was voluntary or involuntaryVhas been associated with higher hip bone loss and fracture.
8<10
Overweight and obese individuals who lose weight either maintain a reduced-obese state or regain lost weight primarily as fat mass. 11 Women who are restrained eaters, who go on long-term diet, or who Bweight cycle[ (weight loss followed by regain) may be at greater risk for low bone mass or osteoporosis. 10, 12, 13 A limited number of previous trials have examined response to weight regain after weight reduction in a single group of women to show that it leads to partial recovery of bone at some anatomical sites. 14<17 In this trial, we use a case-control design to examine whether the rate of bone loss differs in reduced-obese postmenopausal women who maintain their lost weight for 2 years compared with those who regain their lost weight.
METHODS

Participants
Postmenopausal women who successfully completed a 6-month weight loss protocol in our laboratories were eligible for recruitment in this study. Participants were contacted approxi-mately 2 years after their initial inclusion in a 6-month weight reduction program reported previously 1, 2, 18 or that was part of small unpublished pilot studies from 2002 to 2008. To be eligible, postmenopausal women had to be healthyVwithout evidence of osteoporosis, metabolic bone disease, thyroid disorders, immune disease, myocardial infarction, or stroke in the past 6 months, or without kidney stones, diabetes, active cancers, or cancer therapy within the past 12 months. Participants were excluded if they changed their usual daily intake of supplemental calcium or multivitamin/mineral, started a new exercise program, or were taking medications known to influence bone metabolism, including hormone therapy. These studies were approved by the Rutgers University Institutional Review Board. All participants signed an informed consent form.
Protocol
Participants were measured at three time points: baseline (time 0), 6 months of weight reduction (0.5 y), and final (2 y). During the weight loss period (0-0.5 y), participants underwent 6 months of weight loss interventions in our laboratories. In this protocol, participants were counseledVonce weekly for the first 2 months and then twice monthly thereafterVby a registered dietitian to reduce their usual intake by 500 to 600 kcal/day while maintaining usual physical activity levels, as described previously. 1, 2, 18 During the 6-month intervention, volunteers were given a multivitamin containing 400 IU of vitamin D 3 , and total calcium intake was at least 1,000 mg/day in all women. Upon completion of the intervention, all participants were counseled to consume approximately 1.2 g of Ca and 400 IU of vitamin D daily through diet and supplementation. After weight loss, there was a nointervention period (0.5-2.0 y), and participants were categorized according to weight change for this final measurement. Women who maintained their weight were recruited and agematched to a cohort of women who did not meet these criteria and regained their body weight (weight loss regainer [WL-R]) in a case-control design. For eligibility in the weight loss maintainer (WL-M) group, weight regain needed to be less than 25%. The WL-R group was composed of those who regained more than this amount.
Bone and body composition measurements and serum markers
Weight and height were measured to the nearest 0.25 kg and 0.25 cm, respectively, at baseline, after weight loss (0.5 y), and at the 2-year final measurement with a balance beam scale and a stadiometer, respectively (Detecto, Webb City, MO). BMD was measured at the femoral neck, trochanter, spine, total body, 1/3 radius, and ultradistal (UD) radius by dual-energy x-ray absorptiometry (DXA; GE Lunar, Madison, WI; coefficient of variation G1% for all sites). Scans were performed by using enCORE 2004 software (version 8.10.027; GE Lunar). Bone mineral content at each site was also measured. Fat-free soft tissue (FFST), total fat mass, trunk fat, and leg fat were measured by DXA using total body scans and the manufacturer's standard cut lines for leg and trunk regions. Calcium intake was estimated using 3-day food records and analyzed using the US Department of Agriculture database (Food Works Software 10.1; Food Works, Long Valley, NJ).
Fasting morning blood samples were collected from the entire population at baseline and from a subset (n = 22) after 2 years. The bone formation marker osteocalcin (BTI, Stoughton, MA; coefficient of variation G9%) was measured by radioimmunoassay (RIA). Serum N-telopeptide of type I collagen was measured by enzyme-linked immunosorbent assay (Osteomark, Princeton, NJ; coefficient of variation G4.6%). Intact parathyroid hormone (PTH), 25-hydroxyvitamin D (25(OH)D), and estradiol were analyzed by RIA. The coefficient of variation was less than 6.8% for PTH (DSL, Webster, TX; Scantibodies, Santee, CA), less than 12.5% for 25(OH)D (DiaSorin, Stillwater, MN), and less than 12.2% for estradiol (DSL, Webster, TX). Our laboratory participates in a vitamin D external quality assessment scheme (DEQAS) to monitor the performance of the RIA used for 25(OH)D assessment.
Statistical analysis
Changes in body composition, hormones, and bone markers at the three time points (baseline, 0.5 y, and 2 y) between the groups (WL-R and WL-M) were analyzed by a two-factor repeated-measures analysis of variance (ANOVA). If the F test was significant, post hoc analysis was performed using Tukey's pairwise multiple comparison. Changes in bone markers between the groups from baseline to final measurement were analyzed using one-way ANOVA. Annual BMD loss was determined at each site by dividing the percent change in BMD by the number of months during the entire study period for each individual. Multiple regression analysis was used to assess how the change in independent variables (age, leg fat, trunk fat, and FFST) across time influenced the change in BMD at each site. To determine whether weight loss and weight regain will have a similar effect on BMD, we performed a power analysis with > set to 0.05 and with A set to 0.90 using trochanter BMD change during weight loss or maintenance. 5 This analysis indicated that 15 participants per group would be necessary to avoid a type II error, and we included at least five additional participants per group to account for two possible baseline covariates. Values are expressed as mean (SD), except in figures, which include SEM to improve visual clarity. Analysis was performed with SAS statistical software version 9.2 (SAS Institute Inc, Cary, NC).
RESULTS
Ninety women who previously completed weight loss interventions in our laboratory were contacted for this study. Sixty-one responded to these inquiries, and 19 were excluded (owing to initiation of osteoporosis medications, initiation of a rigorous exercise program, cancer diagnosis, initiation of diabetes medications, or refusal to participate; Fig. 1 ). Forty-two postmenopausal women agreed to participate and met criteria for inclusion in this follow-up study. Participants were white (n = 40) and African American (n = 2). Measurements were taken an average of 22 (6) months after the initiation of weight loss. At baseline, there were no significant differences in age, weight, body mass index (BMI), time since menopause, bone, or soft-tissue data between the groups (Table 1 ). In both groups of women, 12% to 15% had surgical or drug-induced menopause. For women who refused to participate or could not be contacted, we analyzed a subset (n = 31); their age, BMI, and weight loss did not differ from those included in this study.
Dietary intake
The baseline total calcium intake (diet and supplement) was 948 (352) mg/day, which did not differ significantly between the WL-M group and the WL-R group. In the parent study (0-6 mo), there were equal numbers (n = 13) of women assigned to normal Ca intake in each weight loss group, and the remaining women were assigned to higher Ca intake in the WL-M (n = 9) and WL-R (n = 7) groups. Total calcium intake during the weight loss intervention was 1,275 (406) 
Body weight and soft tissue
After the 6-month weight loss protocol, there were no significant differences in weight loss (9.3% [3.5%]) in the WL-R and WL-M groups. However, weight loss differed significantly between the groups for two years (Table 1) . During the postYweight loss period (6 mo to 2 y), the WL-M group lost an average of 0.1 (2.0) kg, whereas the WL-R group gained 4.1 (2.3) kg (P e 0.0001; Fig. 2 ). There were also significant differences between the groups in total, trunk, and leg fat, with greater gain in the WL-R group compared with the WL-M group (P G 0.01; Table 1 ). FFST decreased after 2 years in all women (j1.2 [2.2] kg or j2.9% [5.6%]) and did not differ significantly between the groups. Weight and fat mass (total, trunk, and leg) were significantly different between the groups at 2 years (P G 0.001), with higher values in the WL-R group compared with the WL-M group.
BMD and content and serum markers
After 6 months of weight loss, BMD at the trochanter (j3.3% [4.6%]) and spine (j3.1% [5.8%]) decreased in both groups (P e 0.01). In the WL-M group, BMD also decreased at the 1/3 radius and total body ( Table 1) . Bone mineral content decreased only at the 1/3 radius for both groups during the 6 months of weight loss. Although there was a trend for greater BMD loss at the UD radius during the weight loss period in the WL-M group compared with the WL-R group, no other sites showed differences between the groups (Table 1) .
During the postintervention period (6 mo to 2 y), there was a further decrease in BMD at the femoral neck in both groups (Fig. 3) . The trochanter and 1/3 radius BMD continued to decrease during the postintervention period in the WL-M group. Repeated-measures ANOVA showed significantly greater BMD loss across time (2 y) between the groups at the trochanter (P G 0.02) and a trend at the 1/3 radius (Table 1, Fig. 3 ). Across 2 years, BMD decreased significantly at most sites and in both groups (Fig. 3) . Bone mineral content decreased more at the 1/3 radius and trochanter in the WL-M group than in the WL-R group (P G 0.05) after 2 years (Table 1) .
Bone turnover markers and hormone values did not differ between the groups at baseline in the entire population or subset (see Table 1 , Supplemental Digital Content 1, http://links.lww.com/MENO/A66). Across the 2-year period, the bone resorption marker serum N-telopeptide of type I collagen increased more in the WL-M group than in the WL-R group (P G 0.05). In addition, serum PTH tended to increase more in the WL-M group than in the WL-R group (P G 0.09). Changes in serum 25(OH)D, estradiol, and osteocalcin did not differ between the WL-M group and the WL-R group.
Predictors of change in BMD for 2 years
To determine how age and soft tissue influence BMD, we examined whether leg and trunk fat or FFST was important in predicting the relationship using multiple regression analyses (Table 2 ). Age and body composition (leg or trunk fat or FFST) served as explanatory variables for each of the dependent variables. As expected, age did not have a significant independent association with bone loss because there was a relatively narrow age range (53-72 y; Table 2 ). Changes in trochanter BMD were largely explained by changes in leg fat (P G 0.05) and tended to be explained by FFST (P G 0.07). Similarly, leg fat tended to explain changes in total BMD (P G 0.08). 
DISCUSSION
It is well established that weight reduction leads to bone loss. 19 This study was designed to determine whether bone loss continues differently between women who maintain lost weight and women who regain lost weight. We show that overweight and obese postmenopausal women who experience approximately 10% weight reduction and regain approximately 70% of the weight across 18 months have attenuated trochanter and 1/3 radius BMD loss compared with those who maintain a reduced body weight. In women who regain weight, the bone lost during weight reduction is permanent; however, at 2 years, it does not exceed the 0.5% to 1% rate of annual BMD loss expected (depending on the site) because of normal aging. 20<25 These findings suggest that only those women who undergo short-term weight reduction and maintain the lost weight for 2 years continue to lose more BMD at several sites than those who regain the weight.
A few previous studies have addressed the influence of weight loss and weight regain on site-specific BMD.
14<17
The results of these studies have been contradictory, possibly owing to mixed sexes, younger ages of the participants, or shorter study designs. 14<16 In one study, premenopausal women were examined during a 3-month very-low-energy diet (13.2-kg loss), followed by 9 months of randomized controlled walking, and then followed for 2 years after a 62% weight regain. 15 Fogelholm et al 15 reported reduced lumbar spine and femoral neck BMD across 2 years for the entire group, but neither site correlated with weight change. Avenell et al 14 studied BMD in 16 postmenopausal women for 6 months of weight loss followed by 6 months of complete weight regain, and they found greater loss of BMD at the lumbar spine (but not at the femoral neck) than weight-stable women.
14 In another study, 16 frail obese older adults were followed up at 30 months after a 1-year weight loss trial. Their weight remained below baseline and their hip BMD decreased, but there no change in lumbar spine and whole-body BMD. 17 In this same study, physical performance and metabolic profile remained improved after 30 months. 17 In one other study, 23 postmenopausal women were examined at 1 year after 6 months of 5% weight loss. 16 The decrease in lumbar spine and hip BMD attributed to weight loss showed no further decrease during 1 year of weight regain (93% fat mass gain). It was concluded that bone did not recover with weight regain. However, the absence of Bbone recovery[ is less surprising because it would not be expected with fat mass gain 16 and, in fact, BMD loss would be expected because of aging. Our findings show that not only is there no bone recovery with weight regain but also that BMD loss continues or begins at some bone sites. For example, there was no femoral neck BMD loss after 6 months, but there was a significant 2% loss after 2 years. This delayed response to weight loss may be attributed to the bone remodeling transient that may take up to 2 years to complete. 26 Annual bone loss in weight-stable postmenopausal women reaches up to 1% per year, 20<25 similar to women in the current trial who regained their weight (loss at the femoral neck, j1.1% per year; trochanter, j1.3% per year; UD radius, j1.0% per year). In addition, women who successfully maintained a lower body weight for 2 years (WL-M group) showed an even higher annual BMD loss at the trochanter (È3.3% per year) and 1/3 radius (j2.5% per year). There is also elevated bone resorption at 2 years for women who maintained weight loss compared with those who regained body weight; this is consistent with findings of higher bone resorption at 9 months after a short-term (3 mo) weight loss. 27 These findings clarify that bone loss is permanent and continues at a faster rate for at least 2 years for those who do not regain weight. In addition, although the current study observed only one weight loss cycle, bone loss would be expected to be greater with subsequent weight cycling, as shown in rodents. 12 Furthermore, retrospective studies show that multiple episodes of weight loss and regain (weight cycle) increase fracture risk at some sites, 10, 15, 28, 29 suggesting that, even with a normal annual rate of bone loss observed in the Bregain[ group for 2 years, bone quality may be compromised. It is possible that bone loss during the postYweight loss period is delayed because of the bone remodeling transient or because of systemic factors that were altered by lowering body weight, 19, 26 yet some anatomical sites showed faster, rather than slower, bone loss during this postYweight loss period.
The current study demonstrates that loss of FFST and leg fat is a predictor of bone loss, whereas there was no relationship with trunk fat, which represents a site with greater visceral fat. One recent 3-month weight loss study in young men and women 30 examined how soft-tissue compartments explain BMD loss with and without 6 months of weight regain. The authors concluded that changes in soft-tissue composition had little contribution to changes in BMD with weight loss. 30 However, there was no bone loss with weight loss in these participants, possibly owing to the short-term intervention and/or the young age of the participants 19 ; thus, how bone loss is regulated by soft-tissue changes could not be determined. Our results are encouraging because they suggest that fat loss in a predominantly visceral region is not associated with bone loss. Nevertheless, this hypothesis using DXA technology should be confirmed using magnetic resonance imaging and/or quantitative CT to distinguish between different fat depots. Furthermore, it is possible that loss of FFST is exacerbated with each weight loss period, 31 especially in older individuals 32 ; this at least partially explains the lower BMD found in weight cyclers.
This study is limited in its interpretation because it is a case-control design rather than a randomized controlled trial, such that women in the two groups were self-selected. In addition, BMD measurement errors are a concern in the obese population owing to excess and homogeneity of fat tissue surrounding bones 33<36 and/or changes in soft tissue with weight reduction. However, we are less concerned about this potential error for a few reasons. First, the results show bone changes at both central and peripheral bone sites that have more and less adiposity, respectively. In addition, adipose tissue change in this moderate weight loss/regain study is less than in studies showing bone measurement errors. 33, 34 For example, it has been found that 6 kg or more of fat layering on the region being measured (spine or hip) will artificially increase BMD, but the error was not found using smaller amounts of fat. 37 In the current study, total body fat gain in the weight regain group was only 2.8 kg and, therefore, was well below the threshold where error would be expected; the BMD loss during weight stability (0.5-2 y) in the WL-M group cannot be attributed to changes in fat tissue. In addition, the absence of a control weight maintenance group is also a limitation; however, age-related bone loss has been extensively studied in the literature 20<25 and thus is a smaller concern. One strength of this study is that participants were measured by the same certified radiology technician using identical instrumentation across 2 years for all three measurements. Also, although participants had different calcium supplementation assignments during the 5-month weight loss, intake was at or above the recommended level in all individuals, there was a relatively even distribution of both levels of calcium between the groups, and both groups had similar calcium intake during months 6 to 24. It is also possible that this data set is biased because it excludes certain women who were not eligible for follow-up (ie, five women were excluded owing to initiation of osteoporosis medications, and nine women were excluded because they were not interested). However, it was encouraging to note that nearly all women contacted agreed to participate (if they met the inclusion criteria) and that those who we were not contacted or did not participate had age, BMI, and weight loss similar to those included in the study. One further limitation is that we did not monitor physical activity during months 6 to 24 and depended on participants to remember whether there were any extreme changes in physical activity (the reason for the exclusion of one woman during screening). It would be expected that those who maintained their body weight (vs regainers) would have been more physically active to maintain their lower weight and that this would have a beneficial effect on bone, yet BMD loss was greater or similar in the group that successfully maintained weight loss.
CONCLUSIONS
This study shows that weight reductionYinduced bone loss that is apparent immediately after weight loss either continues or first begins at the trochanter, femoral neck, and radius in postmenopausal women. Weight regain does not result in recovery of bone, but it prevents greater loss at the trochanter and 1/3 radius compared with reduced-obese women. Even after weight loss, about 50% of women in the WL-M group were still overweight. Thus, weight loss would be recommended for these individuals, who typically would not be considered at risk for osteoporosis based on their overweight status. There is concern that repeated dieting would enhance bone loss and osteoporosis risk in this population compared with obese women who have been weight-stable, possibly owing to poor bone quality, 38, 39 but specific studies have not been conducted. Hence, questions about weight history should be considered when evaluating risk of osteoporosis. Current recommendations appropriately encourage weight loss in overweight individuals to reduce the risk of comorbidities. Until future prospective studies have addressed how to prevent bone loss after a successful weight reduction, therapies that have been shown to ameliorate bone loss during weight reductionVsuch as adequate calcium and vitamin D, higher protein intake, and increased bone-loading exerciseVshould also be encouraged after weight stabilizes. Whether BMD changes in cortical or trabecular bone affect geometry after weight loss remains an important question in the prevention of fracture risk. Variables without significant findings or trends are not shown (femoral neck, total spine, ultradistal radius, and 1/3 radius).
